Panbela Therapeutics, Inc.
(NASDAQ : PBLA)

( )
PBLA After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -1.31%43.000.9%$1131.01m
ABBVAbbVie, Inc. -0.30%107.401.9%$1036.13m
JNJJohnson & Johnson -0.16%162.910.7%$988.77m
MRKMerck & Co., Inc. -0.11%73.280.7%$937.00m
LLYEli Lilly & Co. -2.07%221.721.1%$592.16m
BMYBristol-Myers Squibb Co. 0.02%59.851.0%$591.86m
AZNAstraZeneca Plc -1.86%57.631.0%$345.66m
NVSNovartis AG -0.34%82.310.2%$159.64m
CRVSCorvus Pharmaceuticals, Inc. -10.17%6.890.7%$147.73m
GSKGlaxoSmithKline Plc -1.14%38.060.2%$133.73m
RGENRepligen Corp. -7.09%285.576.8%$119.88m
RPRXRoyalty Pharma Plc -1.43%36.620.1%$118.91m
SNYSanofi -0.46%47.900.2%$117.35m
VTRSViatris, Inc. -0.87%13.700.0%$115.06m
APLSApellis Pharmaceuticals, Inc. 0.20%35.130.0%$104.57m

Company Profile

Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The firm’s product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in multiple tumor types. The company was founded by Michael T. Cullen, Jr. and Thomas X. Neenan on September 21, 2011 and is headquartered in Waconia, MN.